#ACC21: Bristol Myers backs up its case for heart drug mavacamten as FDA weighs app in cardiomyopathy
When Bristol Myers Squibb signed off on its $13 billion acquisition of MyoKardia back in October, it was making a big bet that lead drug mavacamten could prove a game changer in cardiac myopathy. Now, with the drug up for FDA review, Bristol Myers is backing up its case with new quality of life data.
Patients dosed with myosin inhibitor mavacamten posted a clinically significant increase in scores on the Kansas City Cardiomyopathy Questionnaire, a catch-all summary of symptoms and quality of life markers, over placebo at 30 weeks, according to data from the Phase III EXPLORER-HCM study presented Saturday at the virtual American College of Cardiology meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.